

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高视医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT RENEWAL OF THE EXCLUSIVE DISTRIBUTION AGREEMENT WITH THE GERMANY-BASED SCHWIND

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Mingwang Medical Ltd.* (上海高視明望醫療器械有限公司), a subsidiary of the Company, has formally renewed the exclusive distribution agreement with Schwind eye-tech-solutions GmbH (the “**Germany-based Schwind**”) recently, assuming continued responsibility for the sales, promotion and related services in the Chinese market (including Mainland China, the Hong Kong Special Administrative Region and the Macau Special Administrative Region). As one of the Company’s most important supplier partners, the Germany-based Schwind has maintained stable collaboration with the Company for over 16 years since our initial collaboration in 2009. The renewal of the exclusive distribution agreement further underscores the long-term, stable and strategic mutual-trust relationship between both parties and holds significant importance for consolidating the Group’s competitive advantage in China’s refractive surgery device market.

For over three decades, the Germany-based Schwind has specialized in the R&D of refractive surgery device for ophthalmology, which makes it one of the world’s leading suppliers of excimer laser and femtosecond laser technologies. Its ATOS personalized navigation femtosecond and AMARIS excimer laser series are renowned for innovation, precision and stability, which enjoy international leadership in personalized refractive correction, corneal surgery and other fields. These products have been widely adopted in clinical practice across more than 100 countries and regions worldwide, earning high recognition from refractive surgeons globally.

The renewal of the exclusive distribution agreement with the Germany-based Schwind will further deepen the mutually beneficial cooperative relationship between both parties and bring more opportunities for potential performance growth to the Group, which is in the interest of the Group and its shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, September 30, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purpose only*